Brokerages Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Price Target at $3.33

Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) have been assigned a consensus recommendation of “Hold” from the five analysts that are presently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $3.33.

A number of research analysts have recently commented on SYRS shares. HC Wainwright reissued a “neutral” rating and issued a $1.00 price objective (down previously from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Brookline Capital Management reiterated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. TD Cowen reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Finally, StockNews.com initiated coverage on Syros Pharmaceuticals in a research note on Tuesday, December 31st. They issued a “sell” rating on the stock.

Syros Pharmaceuticals Price Performance

Shares of SYRS stock opened at $0.24 on Thursday. The firm has a market capitalization of $6.52 million, a price-to-earnings ratio of -0.08 and a beta of 1.31. Syros Pharmaceuticals has a 12-month low of $0.18 and a 12-month high of $7.98. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 1.97. The firm has a fifty day moving average of $0.79 and a 200-day moving average of $2.53.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.08. During the same quarter last year, the business earned ($1.35) EPS. On average, equities research analysts forecast that Syros Pharmaceuticals will post -2.94 earnings per share for the current year.

Insiders Place Their Bets

In other Syros Pharmaceuticals news, Director Nancy A. Simonian sold 134,713 shares of the firm’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $0.27, for a total value of $36,372.51. Following the transaction, the director now directly owns 41,070 shares of the company’s stock, valued at $11,088.90. This trade represents a 76.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 12.26% of the company’s stock.

Institutional Trading of Syros Pharmaceuticals

Large investors have recently made changes to their positions in the company. GSA Capital Partners LLP acquired a new position in shares of Syros Pharmaceuticals during the 3rd quarter worth $34,000. Certuity LLC acquired a new position in Syros Pharmaceuticals during the second quarter worth about $109,000. Acadian Asset Management LLC lifted its holdings in shares of Syros Pharmaceuticals by 101.5% in the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock worth $178,000 after acquiring an additional 17,416 shares during the last quarter. Finally, Exome Asset Management LLC boosted its stake in shares of Syros Pharmaceuticals by 87.6% in the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after purchasing an additional 139,400 shares in the last quarter. Institutional investors and hedge funds own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.